<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153243</url>
  </required_header>
  <id_info>
    <org_study_id>#07-061</org_study_id>
    <nct_id>NCT01153243</nct_id>
  </id_info>
  <brief_title>Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes</brief_title>
  <official_title>Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John H. Stroger Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>John H. Stroger Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent clinical trials in non diabetics showed that vitamin D supplementation markedly
      reduced serum levels of C-reactive protein (CRP), interleukin-6, and tissue matrix
      metallo-proteinases. Our study objective is to evaluate if administration of vitamin D in
      African Americans with hypovitaminosis D and DM Type 2 decreases serum levels of
      inflammatory/thrombotic markers such as CRP: Highly Sensitive C Reactive Protein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other questions in our study: In diabetic African American patients,

        1. Prevalence of vitamin D deficiency?

        2. Correlation/relationship between vitamin D levels, Calcium level, parathyroid hormone
           (PTH) and Inflammatory markers

      Setting: All visits will take place at the Fantus Diabetes Clinic.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of inflammatory markers</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of Vitamin D, PTH and Calcium</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Ergocalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The investigators will give intervention group 12 weeks of placebo pill (in pill every week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Active Comparator: Ergocalciferol
The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)</description>
    <arm_group_label>Ergocalciferol</arm_group_label>
    <other_name>Drisdol</other_name>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>The investigators will give control group 12 weeks of 1 placebo pill every week.</description>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African Americans

          -  DM type 2

        Exclusion Criteria:

          -  symptomatic vitamin D deficiency

          -  hypocalcemia

          -  hypercalcemia

          -  malabsorption

          -  liver disease

          -  patients with creatinine &gt; 1.5. (CKD &gt;/= 3)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon Fogelfeld, MD</last_name>
    <role>Study Director</role>
    <affiliation>John H. Stroger Hospital</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>April 6, 2011</last_update_submitted>
  <last_update_submitted_qc>April 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Leon Fogelfeld MD</name_title>
    <organization>John H Stroger Hospital of Cook County</organization>
  </responsible_party>
  <keyword>inflammatory markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

